Neurological Complications Following COVID-19 Vaccination
- 29 November 2022
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Neurology and Neuroscience Reports
- Vol. 23 (1), 1-14
- https://doi.org/10.1007/s11910-022-01247-x
Abstract
Purpose of Review A variety of neurological complications have been reported following the widespread use of the COVID-19 vaccines which may lead to vaccine hesitancy and serve as a major barrier to the public health aim of achieving protective herd immunity by vaccination. In this article, we review the available evidence regarding these neurological adverse events reported, to provide clarity regarding the same so that unfounded fears maybe put to rest. Recent Findings There is a greater than expected occurrence of severe neurological adverse events such as cortical sinus venous thrombosis, Bell’s palsy, transverse myelitis, and Guillain–Barré syndromes along with other common effects such as headaches following different kinds of COVID-19 vaccination. Precipitation of new onset demyelinating brain lesions with or without detection of specific antibodies and worsening of pre-existing neurological disorders (like epilepsy, multiple sclerosis) are also a matter of great concern though no conclusive evidence implicating the vaccines is available as of now. Summary The COVID-19 pandemic is far from being over. Till such time that a truly effective anti-viral drug is discovered, or an appropriate therapeutic strategy is developed, COVID-appropriate behavior and highly effective mass vaccination remain the only weapons in our armamentarium to fight this deadly disease. As often occurs with most therapeutic means for the treatment and prevention of any disease, vaccination against COVID-19 has its hazards. These range from the most trivial ones like fever, local pain and myalgias to several potentially serious cardiac and neurological complications. The latter group includes conditions like cerebral venous thrombosis (curiously often with thrombocytopenia), transverse myelitis and acute inflammatory demyelinating polyneuropathy amongst others. Fortunately, the number of reported patients with any of these serious complications is far too low for the total number of people vaccinated. Hence, the current evidence suggests that the benefits of vaccination far outweigh the risk of these events in majority of the patients. As of now, available evidence also does not recommend withholding vaccination in patients with pre-existing neurological disorders like epilepsy and MS, though adenoviral vaccines should be avoided in those with history of thrombotic events.Keywords
This publication has 111 references indexed in Scilit:
- Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case reportActa Neurologica Belgica, 2021
- COVID-19 vaccines: where we stand and challenges aheadCell Death & Differentiation, 2021
- An Experience of Otorhinolaryngologists as Frontline Worker with Novel Coronavirus: A Qualitative AnalysisIndian Journal of Otolaryngology and Head & Neck Surgery, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- A guide to vaccinology: from basic principles to new developmentsNature Reviews Immunology, 2020
- Oxford–AstraZeneca COVID-19 vaccine efficacyThe Lancet, 2020
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportThe New England Journal of Medicine, 2020
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from RussiaThe Lancet, 2020
- Rapid COVID-19 vaccine developmentScience, 2020